Chest pain and cardiac inflammation: a pharmacist’s guide to pericarditis and myocarditis

CPD
By
AP Staff
-

References

  1. Schulz-Menger J, Collini V, Gröschel J, et al. 2025 ESC guidelines for the management of myocarditis and pericarditis. Eur Heart J 2025;46(40):3952–4041.
  2. Cremer PC, Klein AL, Imazio M. Diagnosis, risk stratification, and treatment of pericarditis: a review. JAMA 2024;332(13):1090–100.
  3. Lazarou E, Tsioufis P, Vlachopoulos C, et al. Acute pericarditis: update. Curr Cardiol Rep 2022;24(8):905–13.
  4. Drazner MH, Bozkurt B, Cooper LT, et al. 2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis. J Am Coll Cardiol 2025;85(4):391–431.
  5. Kitano T, Salmon DA, Dudley MZ, et al. Age- and sex-stratified risks of myocarditis and pericarditis attributable to COVID-19 vaccination: a systematic review and meta-analysis. Epidemiol Rev 2025;47(1):1–11.
  6. Voleti N, Reddy SP, Ssentongo P. Myocarditis in SARS-CoV-2 infection vs COVID-19 vaccination: a systematic review and meta-analysis. Front Cardiovasc Med 2022;9:951314.
  7. Alami A, Krewski D, Farhat N, et al. Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis. BMJ Open 2023;13:e065687.
  8. Australian Technical Advisory Group on Immunisation. COVID-19. In: Australian immunisation handbook. Canberra: Australian Government Department of Health and Aged Care. At: www.immunisationhandbook.health.gov.au/covid-19
  9. Sozzi FB, Gherbesi E, Faggiano A, et al. Viral myocarditis: classification, diagnosis, and clinical implications. Front Cardiovasc Med 2022;9:908663.
  10. Buckley N, ed. Australian medicines handbook. 2026. At: https://amhonline.amh.net.au
  11. Imazio M, Lazaros G, Gattorno M, et al. Anti-interleukin-1 agents for pericarditis: a primer for cardiologists. Eur Heart J 2022;43(31):2946–57.
  12. Urzua Fresno C, Sanchez Tijmes F, Shaw KE, et al. Cardiac imaging in myocarditis: current evidence and future directions. Can J Cardiol 2023;39(7):868–82.
  13. Heart Foundation of Australia. Vaccinations and infections. 2024. At: www.heartfoundation.org.au/your-heart/vaccinations-and-infections
  14. Australian Government Department of Health and Aged Care. ATAGI clinical guidance for COVID-19 vaccine providers. 2025. At: www.health.gov.au/our-work/covid-19-vaccines/advice-for-providers/clinical-guidance
  15. Imazio M, Brucato A, Maestroni S, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation 2011;123(10):1092–7.
  16. Therapeutic Guidelines. Cardiovascular: myocarditis and pericarditis. In: eTG complete. Melbourne: Therapeutic Guidelines Limited. 2023. At: https://app.tg.org.au
  17. National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand. Comprehensive Australian clinical guideline for diagnosing and managing acute coronary syndromes 2025. Heart Lung Circ 2025;34(Suppl 2):S1–75.
  18. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005;112(13):2012–6.
  19. Collini V, De Martino M, Andreis A, et al. Efficacy and safety of colchicine for the treatment of myopericarditis. Heart 2024. [Epub ahead of print]
  20. Gupta T, Gupta M, Sitwala N, et al. Colchicine drug interaction errors and misunderstandings: recommendations for improved evidence-based management. Ann Pharmacother 2022;56(5):563–78.
  21. Lo Presti S, Elajami TK, Reyaldeen R, et al. Emerging therapies for recurrent pericarditis: interleukin-1 inhibitors. J Am Heart Assoc 2021;10(19):e021685.
  22. Sinagra G, Merlo M, Bussani R. Caution with the use of NSAIDs in myocarditis. QJM 2022;116(2):153.